ReviewCardiovascular research2010
The ubiquitin-proteasome system in myocardial ischaemia and preconditioning.
Review in Cardiovascular research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Integrated microRNA and mRNA responses to acute human left ventricular ischemia.Physiological genomics · 2015Trial
- Deficiency of the Immunoproteasome LMP10 Subunit Attenuates Angiotensin II-Induced Cardiac Hypertrophic Remodeling via Autophagic Degradation of gp130 and IGF1R.Frontiers in physiology · 2020Article
- Phosphorylation Modifications Regulating Cardiac Protein Quality Control Mechanisms.Frontiers in physiology · 2020Review
- Targeting Protein Kinase G to Treat Cardiac Proteotoxicity.Frontiers in physiology · 2020Review
- The role of ubiquitin in cardiac ischemia-reperfusion injury.American journal of physiology. Heart and circulatory physiology · 2019Article
- Proteostasis in cardiac health and disease.Nature reviews. Cardiology · 2017Review
- Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.Antioxidants & redox signaling · 2014Review
- Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond.Journal of molecular and cellular cardiology · 2014Review
- Upregulation of proteasome activity rescues cardiomyocytes following pulse treatment with a proteasome inhibitor.American journal of cardiovascular disease · 2014Article
- The ubiquitin proteasome system in human cardiomyopathies and heart failure.American journal of physiology. Heart and circulatory physiology · 2013Review
- Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure.Circulation. Heart failure · 2013Article
- Hypoxia-inducible factor-1α and vascular endothelial growth factor in the cardioprotective effects of intermittent hypoxia in rats.Upsala journal of medical sciences · 2013Article
- The ubiquitin proteasome system and myocardial ischemia.American journal of physiology. Heart and circulatory physiology · 2013Review
- Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice.Circulation research · 2012Article
- Post-translational modification of cardiac proteasomes: functional delineation enabled by proteomics.American journal of physiology. Heart and circulatory physiology · 2012Review
- Role of various proteases in cardiac remodeling and progression of heart failure.Heart failure reviews · 2012Review
- The ubiquitin-proteasome system and cardiovascular disease.Progress in molecular biology and translational science · 2012Review
- Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.International journal of proteomics · 2012Article
- The role of the proteasome in heart disease.Biochimica et biophysica acta · 2011Review
- Modulation of Na(+)-K(+)-ATPase cell surface abundance through structural determinants on the α1-subunit.American journal of physiology. Cell physiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The ubiquitin-proteasome system (UPS) represents the major pathway for degradation of intracellular proteins. This article reviews the major components and configurations of the UPS including the 26S proteasome and 11S activated proteasome relevant to myocardial ischaemia. We then present the evidence that the UPS is dysfunctional during myocardial ischaemia as well as potential consequences of this, including dysregulation of target substrates, many of them active signalling proteins, and accumulation of oxidized proteins. As part of this discussion, potential mechanisms, including ATP depletion, inhibition by insoluble protein aggregates, and oxidation of proteasome and regulatory particle subunits, are discussed. Finally, the evidence suggesting a role for the UPS in ischaemic preconditioning is presented. Much of this is inferential but clearly indicates the need for additional research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.